LG-2527
Clinical data | |
---|---|
Drug class | Progestin; Progestogen |
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.